Literature DB >> 21176853

Myocardial delayed enhancement in paucisymptomatic nonischemic dilated cardiomyopathy.

Pier Giorgio Masci1, Andrea Barison, Giovanni Donato Aquaro, Alessandro Pingitore, Rita Mariotti, Alberto Balbarini, Claudio Passino, Massimo Lombardi, Michele Emdin.   

Abstract

OBJECTIVES: We investigated the prognostic role of myocardial fibrosis by delayed enhancement (DE) cardiovascular magnetic resonance (CMR) in nonischemic dilated cardiomyopathy (NICM) patients with no or mild symptoms of heart failure (HF).
METHODS: A prospective cohort of 125 NICM patients (82 males, age 59±14years, mean±SD) with echocardiographic evidence of left ventricular (LV) systolic dysfunction (mean ejection-fraction 33±10%), without (stage B) or with history of mild HF symptoms (stage C, NYHA classes I-II) was enrolled. The end-point was a composite of cardiac death and HF hospitalization.
RESULTS: Fifty (40%) patients showed myocardial DE, representing 12±7% of LV mass. During a median follow-up of 14.2months, 16 (32%) patients with DE experienced a composite event versus only 6 (8%) patients without DE (Kaplan-Meier survival curve, p=0.001). After correction for age, CMR-derived LV and right ventricular volumes, echocardiographic measurements of LV diastolic function and Doppler-estimated systolic pulmonary artery pressure, the presence of DE remained a strong and independent predictor of cardiac death or HF hospitalization (hazard ratio: 5.32, 95% confidence intervals 1.60 to 17.63, p=0.006).
CONCLUSIONS: In NICM patients with no or mild HF symptoms, the presence of myocardial DE is a strong predictor of worse clinical outcome even after correction for other established prognostic determinants. Contrast-enhanced CMR may be useful in prognostic stratification from the early stages of NICM.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21176853     DOI: 10.1016/j.ijcard.2010.11.005

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  9 in total

1.  Myocardial fibrosis and quality of life in patients with non-ischemic cardiomyopathy: a cardiovascular magnetic resonance imaging study.

Authors:  Razi Khan; David Massel; John Stirrat; David Scholl; Gerald Wisenberg; Terry Thompson; Maria Drangova; James A White
Journal:  Int J Cardiovasc Imaging       Date:  2012-08-09       Impact factor: 2.357

Review 2.  Impact of cardiac magnetic resonance imaging in non-ischemic cardiomyopathies.

Authors:  Kevin Kalisz; Prabhakar Rajiah
Journal:  World J Cardiol       Date:  2016-02-26

3.  Correlation of left ventricular dyssynchrony on gated myocardial perfusion SPECT analysis with extent of late gadolinium enhancement on cardiac magnetic resonance imaging in hypertrophic cardiomyopathy.

Authors:  Hideaki Yuki; Daisuke Utsunomiya; Shinya Shiraishi; Seiji Takashio; Fumi Sakamoto; Noriko Tsuda; Seitaro Oda; Masafumi Kidoh; Takeshi Nakaura; Kenichi Tsujita; Yasuyuki Yamashita
Journal:  Heart Vessels       Date:  2017-12-11       Impact factor: 2.037

Review 4.  Myocardial interstitial remodelling in non-ischaemic dilated cardiomyopathy: insights from cardiovascular magnetic resonance.

Authors:  Andrea Barison; Chrysanthos Grigoratos; Giancarlo Todiere; Giovanni Donato Aquaro
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

5.  Cardiac magnetic resonance and galectin-3 level as predictors of prognostic outcomes for non-ischemic cardiomyopathy patients.

Authors:  Da-Jun Hu; Jing Xu; Wei Du; Jian-Xin Zhang; Min Zhong; Ya-Nan Zhou
Journal:  Int J Cardiovasc Imaging       Date:  2016-08-26       Impact factor: 2.357

Review 6.  The Role of AI in Characterizing the DCM Phenotype.

Authors:  Clint Asher; Esther Puyol-Antón; Maleeha Rizvi; Bram Ruijsink; Amedeo Chiribiri; Reza Razavi; Gerry Carr-White
Journal:  Front Cardiovasc Med       Date:  2021-12-21

7.  Prognostic factors associated with left ventricular non-compaction: A PRISMA-compliant meta-analysis.

Authors:  Ze-Guang Yang; Zhi-Jie Liu; Xiang-Xin Zhang; Li Wang
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

Review 8.  Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments.

Authors:  Nicoletta Orphanou; Efstathios Papatheodorou; Aris Anastasakis
Journal:  Heart Fail Rev       Date:  2021-07-14       Impact factor: 4.654

9.  High resolution systematic digital histological quantification of cardiac fibrosis and adipose tissue in phospholamban p.Arg14del mutation associated cardiomyopathy.

Authors:  Johannes M I H Gho; René van Es; Nikolas Stathonikos; Magdalena Harakalova; Wouter P te Rijdt; Albert J H Suurmeijer; Jeroen F van der Heijden; Nicolaas de Jonge; Steven A J Chamuleau; Roel A de Weger; Folkert W Asselbergs; Aryan Vink
Journal:  PLoS One       Date:  2014-04-14       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.